🧪
hypothesis

GBA1-Deficiency Disrupts Mitochondrial- Lysosomal Contact Sites by Reducing Miro1 Degradation, Creating a Pink1-Parkin Mitophagy Blockade

Hypothesis

GBA1-Deficiency Disrupts Mitochondrial- Lysosomal Contact Sites by Reducing Miro1 Degradation, Creating a Pink1-Parkin Mitophagy Blockade

GBA1 deficiency leads to glucosylceramide accumulation in the inner mitochondrial membrane (as shown by lipidomics of patient fibroblasts), which directly stabilizes Miro1 protein levels by inhibiting the mitochondrial protease LONP1.
🧬 GBA1🩺 neurodegeneration🎯 Composite 75%💱 $0.52▼3.5%active
EvidencePending (0%)📖 5 cit🗣 1 debates 5 support 1 oppose
⚠ Orphaned Senate Quality Gates →
🏆 ChallengeSolve: GBA1-Deficiency Disrupts Mitochondrial- Lysosomal Contact Sites by Reduci$125K →
☰ Compare⚛️ Collide
📄 Export LaTeX
arXiv PreprintNeurIPSNature MethodsPLOS ONE
📖 Export BibTeXinteract with this hypothesis
Composite75%

🧪 Overview

GBA1 deficiency leads to glucosylceramide accumulation in the inner mitochondrial membrane (as shown by lipidomics of patient fibroblasts), which directly stabilizes Miro1 protein levels by inhibiting the mitochondrial protease LONP1. Miro1 is a calcium-sensitive adaptor that tethers mitochondria to the microtubule motor complex; under normal conditions, Miro1 is ubiquitinated by the Pink1-Parkin pathway and degraded to enable mitophagosome formation. When GlcCer stabilizes Miro1, damaged mitochondria remain physically anchored, preventing their delivery to lysosomes via mitophagy. The accumulated dysfunctional mitochondria generate increased ROS, which oxidizes and inactivates GCase in a feedforward loop. Simultaneously, the impaired mitophagy prevents turnover of mitochondrial SNCA nucleation sites, as mitochondria serve as platforms for initial SNCA oligomerization in neurons. VPS35 dysfunction (as in D620N mutation) worsens this by impairing trafficking of both GCase and the mitochondria-lysosome tethering machinery. The prediction is that Miro1 knockdown or pharmacological destabilization (with relevant compounds) will restore mitophagy and break the cycle.

...

🧬 Mechanism

🧬 Curated Mechanism Pathway

Curated pathway from expert analysis

flowchart TD
    A["GBA1 GCase Deficiency<br/>GlcCer Accumulation"]
    B["Mitochondrial Lysosomal Contact Disruption<br/>Organelle Crosstalk Loss"]
    C["LONP1 Protease Inhibition<br/>Miro1 Stabilization"]
    D["Miro1 Motor Adaptor Persistence<br/>Damaged Mitochondria Stay Motile"]
    E["PINK1 Parkin Mitophagy Blockade<br/>Ubiquitin Clearance Failure"]
    F["Damaged Mitochondria Retention<br/>ROS and Bioenergetic Stress"]
    G["SNCA Aggregation Susceptibility<br/>PD Neurodegeneration"]
    A --> B
    B --> C
    C --> D
    D --> E
    E --> F
    F --> G
    style A fill:#7b1fa2,stroke:#ce93d8,color:#ce93d8
    style G fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a

⚖️ Evidence

⚖️ Evidence Matrix5 supports0 contradicts
Supports
Proteolytic rewiring of mitochondria by LONP1 directs cell identity switching of adipocytes.
Nat Cell Biol2023PMID:37217599medium
Supports
Readdressing the Localization of Apolipoprotein E (APOE) in Mitochondria-Associated Endoplasmic Reticulum (ER) Membranes (MAMs): An Investigation of the Hepatic Protein-Protein Interactions of APOE with the Mitochondrial Proteins Lon Protease (LONP1), Mitochondrial Import Receptor Subunit TOM40 (TOMM40) and Voltage-Dependent Anion-Selective Channel 1 (VDAC1).
Int J Mol Sci2024PMID:39408926medium
Supports
LonP1 Links Mitochondria-ER Interaction to Regulate Heart Function.
Research (Wash D C)2023PMID:37333972medium
Supports
Glucocerebrosidase is imported into mitochondria and preserves complex I integrity and energy metabolism.
Nat Commun2023PMID:37024507medium
Supports
Modulation of Lonp1 Activity by Small Compounds.
Biomolecules2025PMID:40305312medium
📖 Linked Papers

No linked papers recorded for this hypothesis yet.

🏥 Translation

🧬 3D Protein Structure — GBA1

🧬 PDB 2V3D Click to expand

Experimental structure from RCSB PDB | Powered by Mol*

💉 Clinical Trials (5)

0
Active
0
Completed
0
Total Enrolled
PHASE2
Highest Phase
Ambroxol in New and Early DLB, A Phase IIa Multicentre Randomized Controlled Double Blind Clinical TrialPHASE2
UNKNOWN·NCT04588285 · Helse Fonna
Dementia With Lewy Bodies
Ambroxol Placebo
Prevent Cognitive Decline in GBA-associated Parkinson's DiseasePHASE2
NOT_YET_RECRUITING·NCT07055087 · University Hospital Tuebingen
Parkinson's Disease
Prasinezumab Sodium Chloride
Understanding Alpha-Synuclein Spread in Parkinson's Disease Through Blood Biomarkers and NeuroimagingNA
NOT_YET_RECRUITING·NCT07474779 · University of Pavia
Parkinson's Disease (PD) GBA1 Parkinson Disease REM Sleep Behavior Disorder (iRBD)
brain imaging blood draw Skin biopsy
Ioflupane I123 (DaTSCAN) and Positron Emission Tomography-computed Tomography Fludeoxyglucose (PET-CT FDG) to Assess Brain Function of Parkinson Patients With Different Genetic CharacteristicsUnknown
UNKNOWN·NCT01089283 · Tel-Aviv Sourasky Medical Center
Parkinson Disease
Drug Discovery for Parkinson's With Mutations in the GBA GeneUnknown
RECRUITING·NCT05536388 · New York Stem Cell Foundation Research Institute
Parkinson Disease Gaucher Disease Healthy
Biological Sample Collection

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for GBA1 →

No DepMap CRISPR Chronos data found for GBA1.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend
Stable
7d Momentum
▲ 0.0%
Volatility
High
0.1206
Events (7d)
1
Price History
▼3.5%

💾 Resource Usage

No resource usage or linked notebooks recorded for this hypothesis yet.

🔮 Predictions

🔎 Predictions vs Observations2 predictions · 0 with recorded observations
PredictionPredictedObservedStatusConf
IF Miro1 is genetically knocked down (via shRNA or CRISPRi) in GBA1-deficient patient-derived neurons THEN mitochondrial-lysosomal contact site frequency (measured by MCS-anchors live-cell imaging) wiMiro1 knockdown reduces mitochondrial-lysosomal contact site frequency and restores mitophagy flux in GBA1-deficient neurons to near-wildtype levels— no observation —pending0.65
IF glucosylceramide (GlcCer) accumulation is reduced via GCase enzyme replacement (ambroxol) or substrate reduction therapy in GBA1-deficient fibroblasts THEN Miro1 protein levels will decrease by >40GlcCer reduction normalizes Miro1 protein levels and restores LONP1 protease activity in GBA1-deficient cells— no observation —pending0.58
🔮 Falsifiable Predictions (2)
pendingconf 65%
IF Miro1 is genetically knocked down (via shRNA or CRISPRi) in GBA1-deficient patient-derived neurons THEN mitochondrial-lysosomal contact site frequency (measured by MCS-anchors live-cell imaging) will decrease by >50% and mitophagy flux (mt-Keima ratio) will increase to ≥70% of wild-type levels wi
Predicted outcome: Miro1 knockdown reduces mitochondrial-lysosomal contact site frequency and restores mitophagy flux in GBA1-deficient neurons to near-wildtype levels
Falsification: Miro1 knockdown fails to reduce contact site frequency or does not significantly increase mitophagy flux (p>0.05, n≥3 independent neuronal differentiations), indicating Miro1 stabilization is not the
pendingconf 58%
IF glucosylceramide (GlcCer) accumulation is reduced via GCase enzyme replacement (ambroxol) or substrate reduction therapy in GBA1-deficient fibroblasts THEN Miro1 protein levels will decrease by >40% and LONP1 protease activity will increase correspondingly within 48 hours of treatment.
Predicted outcome: GlcCer reduction normalizes Miro1 protein levels and restores LONP1 protease activity in GBA1-deficient cells
Falsification: GlcCer reduction does not significantly alter Miro1 protein levels or LONP1 activity (p>0.05, n≥4 patient lines), disproving the proposed GlcCer-Miro1-LONP1 mechanistic axis
View on SciDEX ↗